Chemomab Therapeutics Statistics
Share Statistics
Chemomab Therapeutics has 942.83K
shares outstanding. The number of shares has increased by 32.62%
in one year.
| Shares Outstanding | 942.83K |
| Shares Change (YoY) | 32.62% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 0.04% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 1,865 |
| FTD / Avg. Volume | 0.5% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -2106.84 and the forward
PE ratio is -3.03.
Chemomab Therapeutics's PEG ratio is
21.25.
| PE Ratio | -2106.84 |
| Forward PE | -3.03 |
| PS Ratio | 0 |
| Forward PS | 0 |
| PB Ratio | 2.17 |
| P/FCF Ratio | -1.91 |
| PEG Ratio | 21.25 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Chemomab Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.98,
with a Debt / Equity ratio of 0.02.
| Current Ratio | 4.98 |
| Quick Ratio | 4.98 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | -22.08 |
| Debt / FCF | -0.02 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-697.25 |
| Employee Count | 20 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by 86.39% in the
last 52 weeks. The beta is 0.67, so Chemomab Therapeutics's
price volatility has been higher than the market average.
| Beta | 0.67 |
| 52-Week Price Change | 86.39% |
| 50-Day Moving Average | 1.29 |
| 200-Day Moving Average | 1.56 |
| Relative Strength Index (RSI) | 59.69 |
| Average Volume (20 Days) | 373,488 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -14.74K |
| Net Income | -13.95K |
| EBITDA | -14.67K |
| EBIT | -14.74K |
| Earnings Per Share (EPS) | -0.02 |
Full Income StatementBalance Sheet
The company has 6.07M in cash and 324K in
debt, giving a net cash position of 5.75M.
| Cash & Cash Equivalents | 6.07M |
| Total Debt | 324K |
| Net Cash | 5.75M |
| Retained Earnings | -102.62M |
| Total Assets | 16.96M |
| Working Capital | 12.82M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -15.46M
and capital expenditures 0, giving a free cash flow of -15.39M.
| Operating Cash Flow | -15.46M |
| Capital Expenditures | n/a |
| Free Cash Flow | -15.39M |
| FCF Per Share | -0.05 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
